Skip to main content

Table 4 Clinical and dosimetric factors associated with symptoms after CIRT

From: Carbon-ion radiotherapy for non-small cell lung cancer with interstitial lung disease: a retrospective analysis

 

no grade change (n = 24)

grade progression (n = 5)

p-value

Clinical factors

 Age (yr), median (range)

72.0 (62–90)

76.0 (71–86)

0.224

 Performance Status (0/1/2)

13/9/2

1/4/0

0.330

 Severity of ILD (JRS) (1/2/3/4)

9/7/4/4

0/3/2/0

0.434

 mMRC scale (1/2/3/4/5)

0/9/6/5/4

0/2/0/3/0

0.952

 Tumor location (U/L)

11/13

3/2

1.000

 Tumor size (mm), median (range)

34.0 (17–58)

31.0 (22–63)

0.544

 serum KL-6, median (range)

880.5 (325–2410)

544.0 (466–1199)

0.260

 serum SP-D, median (range)

152.0 (60–502)

105.0 (31–140)

0.036

Respiratory function, median (range)

 %VC

90.7 (43.5–130.4)

86.7 (64.9–107.3)

0745

 %FVC

81.8 (37.9–117.6)

82.7 (52.8–98.7)

0.820

 FEV1.0 (L)

2.0 (1.13–2.92)

2.0 (1.47–2.96)

1.000

 FEV1.0/VC (%)

80.7 (54.0–91.2)

78.6 (72.7–99.7)

0.696

 %DLco

50.7 (15.5–92.2)

70.7 (39–235.5)

0.474

 Not evaluated

3

0

 

Dose-volume metrics, median (range)

 PTV (mL)

82.9 (34.6–345.9)

88.1 (52.3–1319.8)

0.507

 Total dose (Gy[RBE]),

52.8 (46–72)

50.0 (50–72)

0.5745

Dosimetric factors of the lung (%), median (range)

 V5

8.7 (3.0–20.6)

14.2 (10.9–34.8)

0.026

 V10

7.6 (2.6–18.3)

11.9 (8.4–32.8)

0.033

 V15

5.6 (2.2–13.6)

8.0 (7.1–27.1)

0.074

 V20

5.0 (3.0–20.6)

7.3 (6.2–18.0)

0.069

 V25

4.2 (1.8–11.0)

5.4 (3.3–16.8)

0.237

 V30

3.7 (1.5–9.0)

4.9 (2.8–15.9)

0.286

 V35

3.4 (1.4–8.5)

4.4 (2.5–5.0)

0.260

 V40

3.1 (1.3–8.0)

4.0 (2.2–14.0)

0.260

Mean Lung Dose (Gy[RBE])

2.8 (1.0–6.4)

3.8 (3.0–12.2)

0.075

  1. Abbreviations: CIRT carbon ion radiotherapy, ILD interstitial lung disease, JRS Japanese Respiratory Society, mMRC scale the modified Medical Research Council scale, KL-6 Krebs von den Lungen-6, SP-D surfactant protein D, VC vital capacity, FVC forced vital capacity, FEV1.0 Forced Expiratory Volume in one second, DLco diffusion capacity of the lung, PTV planning target volume, RBE relative biological effectiveness